[Interleukin 2 revival: a revisited model and new therapeutic applications]

Med Sci (Paris). 2016 Jun-Jul;32(6-7):612-8. doi: 10.1051/medsci/20163206025. Epub 2016 Jul 12.
[Article in French]

Abstract

Interleukin-2, a cytokine identified as T-cell growth factor, has long been regarded as central to the development and effector activities of immune responses. Several gene knockout mouse studies and observations in humans, however, have undermined that vision, and the discovery of regulatory T cells showed that IL-2, in contrast to the accepted dogma, has the essential function of promoting (1) homeostasis and (2) the function of these T regulator cells the which, limit the action of the effector cells, in particular to prevent the autoimmune reaction drifts. This new paradigm has major implications on the use of IL-2 in therapy, and creates new strategies to manipulate the Teffectors/Tregulators balance.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / metabolism
  • Dose-Response Relationship, Drug
  • Homeostasis
  • Humans
  • Inflammation / immunology
  • Inflammation / metabolism
  • Interleukin-2 / physiology*
  • Interleukin-2 / therapeutic use
  • Models, Biological*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / metabolism
  • Therapies, Investigational / methods*

Substances

  • Interleukin-2